Pradžia › Melanoma › Delaveras
Melanoma klinikiniai tyrimai Delaveras
6 tyrimai dėl Melanoma ieško dalyvių vietose Delaveras.
Miestai Delaveras
Oficialus tyrimo tekstas (anglų kalba)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT05136196A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- Alfred I duPont Hospital for Children, Wilmington
Renkami dalyviai2 fazė
Iki 25 metų · Visoms lytims · Atnaujinta 2026-09-24 · NCT07621614Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Beebe Medical Center, Lewes
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- ir dar 4
Renkami dalyviai3 fazė
Amžius 75 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT07068074Project: Every Child for Younger Patients With Cancer
- Alfred I duPont Hospital for Children, Wilmington
Renkami dalyviaiStebimasis tyrimas
Iki 25 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT02402244Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- ir dar 1
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-17 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Newark
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.